Prognostic value of neutrophil distribution in cholangiocarcinoma

World Journal of Gastroenterology

Volumn 21, Issue 16, 2015, Pages 4961-4968

  Mao, Zhi Yuan ^a   Zhu, Guang Qing ^a   Xiong, Mei ^a   Ren, Li ^a   Bai, Li ^b  

^a AIR FORCE GENERAL HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CD15; Cholangiocarcinoma; Neutrophils; Prognosis; Surgery; Tumor microenvironment

Indexed keywords

CD15 ANTIGEN; FUCOSYLTRANSFERASE; FUT4 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CELL DENSITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OVERALL SURVIVAL; PATHOLOGY; TISSUE SECTION; TUMOR MICROENVIRONMENT; BILE DUCT NEOPLASMS; CHI SQUARE DISTRIBUTION; CHOLANGIOCARCINOMA; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; UPREGULATION;

ANTIGENS, CD15; BILE DUCT NEOPLASMS; BIOMARKERS, TUMOR; CHI-SQUARE DISTRIBUTION; CHOLANGIOCARCINOMA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FUCOSYLTRANSFERASES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHILS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 84928399984     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i16.4961     Document Type: Article

References (50)

1. Welzel TM, Mellemkjaer L, Gloria G, Sakoda LC, Hsing AW, El Ghormli L, Olsen JH, McGlynn KA. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide casecontrol study. Int J Cancer 2007;120:638-641 [PMID: 17109384 DOI: 10.1002/ijc.22283]
2. Donato F, Gelatti U, Tagger A, Favret M, Ribero ML, Callea F, Martelli C, Savio A, Trevisi P, Nardi G. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001;12:959-964 [PMID: 11808716 DOI: 10.1023/A:1013747228572]
3. El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, Giordano TP. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A populationbased study of U. S. veterans. Hepatology 2009;49:116-123 [PMID: 19085911 DOI: 10.1002/hep. 22606]
4. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005;128:620-626 [PMID: 15765398]
5. Lee TY, Lee SS, Jung SW, Jeon SH, Yun SC, Oh HC, Kwon S, Lee SK, Seo DW, Kim MH, Suh DJ. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol 2008;103:1716-1720 [PMID: 18557716 DOI: 10.1111/j.1572-0241.2008.01796.x]
6. Zhou YM, Yin ZF, Yang JM, Li B, Shao WY, Xu F, Wang YL, Li DQ. Risk factors for intrahepatic cholangiocarcinoma: a casecontrol study in China. World J Gastroenterol 2008;14:632-635 [PMID: 18203300 DOI: 10.3748/wjg.14.632]
7. Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest 2012;122:3914-3918 [PMID: 23023701 DOI: 10.1172/JCI63065]
8. Yamamoto S, Kubo S, Hai S, Uenishi T, Yamamoto T, Shuto T, Takemura S, Tanaka H, Yamazaki O, Hirohashi K, Tanaka T. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004;95:592-595 [PMID: 15245596 DOI: 10.1111/j.1349-7006.2004.tb02492.x]
9. Chapman MH, Webster GJ, Bannoo S, Johnson GJ, Wittmann J, Pereira SP. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol 2012;24:1051-1058 [PMID: 22653260 DOI: 10.1097/MEG.0b013e3283554bbf]
10. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzén H, Almer S, Granath F, Broomé U. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-327 [PMID: 11867174 DOI: 10.1016/S0168-8278 (01) 00288-4]
11. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-678 [PMID: 20101749 DOI: 10.1002/hep. 23294]
12. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, Van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009;50:158-164 [PMID: 19012991 DOI: 10.1016/j.jhep. 2008.08.013]
13. Boberg KM, Bergquist A, Mitchell S, Pares A, Rosina F, Broomé U, Chapman R, Fausa O, Egeland T, Rocca G, Schrumpf E. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002;37:1205-1211 [PMID: 12408527 DOI: 10.1080/003655202760373434]
14. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011;54:173-184 [PMID: 21488076 DOI: 10.1002/hep. 24351]
15. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-267 [PMID: 19501929 DOI: 10.1016/j.jhep. 2009.04.009]
16. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011;54:1842-1852 [PMID: 21793028 DOI: 10.1002/hep. 24570]
17. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]
18. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K, Takenaka K. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005;103:1856-1864 [PMID: 15779015 DOI: 10.1002/cncr.20976]
19. Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, Moratti R, Corazza GR. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 2008;19:353-358 [PMID: 17962206 DOI: 10.1093/annonc/mdn290]
20. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, Von Der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009;27:4709-4717 [PMID: 19720929 DOI: 10.1200/JCO.2008.18.9498]
21. Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol 2011;54:497-505 [PMID: 21112656 DOI: 10.1016/j.jhep. 2010.07.044]
22. Hughes-Benzie RM, Hunter AG, Allanson JE, Mackenzie AE. Simpson-Golabi-Behmel syndrome associated with renal dysplasia and embryonal tumor: localization of the gene to Xqcen-q21. Am J Med Genet 1992;43:428-435 [PMID: 1605222 DOI: 10.1038/sj.bjc.6602702]
23. Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Von Der Maase H, Eggermont AM, Keilholz U. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 2007;25:1562-1569 [PMID: 17443000 DOI: 10.1200/JCO.2006.09.0274]
24. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, Bureau G, Dabouis G, Van Cutsem O, Mommen P, Ninane V, Klastersky J. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523-533 [PMID: 10931451 DOI: 10.1002/1097-0142]
25. Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, Kim YJ. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011;104:504-510 [PMID: 21618251 DOI: 10.1002/jso.21986]
26. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, Miyazaki A, Gunji H, Yamamoto H, Nagata M. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010;13:170-176 [PMID: 20820986 DOI: 10.1007/s10120-010-0554-3]
27. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215-220 [PMID: 18424885 DOI: 10.1159/000127412]
28. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol 2013;23:200-207 [PMID: 23403174 DOI: 10.1016/j.semcancer.2013.02.001]
29. Kerr MA, Stocks SC. The role of CD15-(Le (X))-related carbohydrates in neutrophil adhesion. Histochem J 1992;24:811-826 [PMID: 1362195 DOI: 10.1007/BF01046353]
30. De Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-423 [PMID: 15894262 DOI: 10.1016/j.ccr.2005.04.014]
31. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867 [PMID: 12490959 DOI: 10.1038/nature01322]
32. Daniel D, Chiu C, Giraudo E, Inoue M, Mizzen LA, Chu NR, Hanahan D. CD4+ T cell-mediated antigen-specific immuno-therapy in a mouse model of cervical cancer. Cancer Res 2005;65:2018-2025 [PMID: 15753402 DOI: 10.1158/0008-5472. CAN-04-3444]
33. Strell C, Lang K, Niggemann B, Zaenker KS, Entschladen F. Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1. Exp Cell Res 2010;316:138-148 [PMID: 19747913 DOI: 10.1016/j.yexcr.2009.09.003]
34. Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 2005;65:8896-8904 [PMID: 16204061 DOI: 10.1158/0008-5472. CAN-05-1734]
35. Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, Cucchetti A, D'Errico-Grigioni A, Golfieri R, Pinna AD. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation 2011;91:1279-1285 [PMID: 21617590 DOI: 10.1097/TP.0b013e3182187cf0]
36. Huang ZL, Luo J, Chen MS, Li JQ, Shi M. Blood neutrophil-tolymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2011;22:702-709 [PMID: 21514523 DOI: 10.1016/j.jvir.2010.12.041]
37. Chen TM, Lin CC, Huang PT, Wen CF. Neutrophil-tolymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol 2012;27:553-561 [PMID: 21913982 DOI: 10.1111/j.1440-1746.2011.06910.x]
38. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006;103:12493-12498 [PMID: 16891410 DOI: 10.1073/pnas.0601807103]
39. Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007;104:20262-20267 [PMID: 18077379 DOI: 10.1073/pnas.0706438104]
40. Shojaei F, Singh M, Thompson JD, Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci USA 2008;105:2640-2645 [PMID: 18268320 DOI: 10.1073/pnas.0712185105]
41. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006;6:173-182 [PMID: 16498448 DOI: 10.1038/nri1785]
42. Benelli R, Albini A, Noonan D. Neutrophils and angiogenesis: potential initiators of the angiogenic cascade. Chem Immunol Allergy 2003;83:167-181 [PMID: 12947984 DOI: 10.1159/000071560]
43. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-744 [PMID: 11025665 DOI: 10.1038/35036374]
44. Faris JE, Zhu AX. Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci 2012;19:326-336 [PMID: 22318523 DOI: 10.1007/s00534-011-0496-0]
45. Voss JS, Holtegaard LM, Kerr SE, Fritcher EG, Roberts LR, Gores GJ, Zhang J, Highsmith WE, Halling KC, Kipp BR. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol 2013;44:1216-1222 [PMID: 23391413 DOI: 10.1016/j.humpath.2012.11.006]
46. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012;142:1021-1031. e15 [PMID: 22178589 DOI: 10.1053/j.gastro.2011.12.005]
47. Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, Hirohashi S, Shibata T. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 2009;100:1257-1266 [PMID: 19319137 DOI: 10.1038/sj.bjc.6604988]
48. El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CD. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 2012;30:1646-1651 [PMID: 21748296 DOI: 10.1007/s10637-011-9719-0]
49. Takahashi H, Ojima H, Shimizu H, Furuse J, Furukawa H, Shibata T. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma. Jpn J Clin Oncol 2014;44:570-578 [PMID: 24755544 DOI: 10.1093/jjco/hyu045]
50. El-Khoueiry AB, Rankin C, Siegel AB, Iqbal S, Gong IY, Micetich KC, Kayaleh OR, Lenz HJ, Blanke CD. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 2014;110:882-887 [PMID: 24423918 DOI: 10.1038/bjc.2013.801]